- Achieved $8.7 Million in Net Revenue from Sales of COSELA® (trilaciclib) in the Second Quarter of 2022 and $10.6 Million in Total Revenue -
- Completed Patient Enrollment in Pivotal Phase 3 Trial of Trilaciclib in Metastatic Colorectal Cancer (mCRC) (PRESERVE 1) -
Read more at globenewswire.com